Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs. Drug pricing reform. Food and Drug Administration legislative and regulatory issues.
2026 · 1st Quarter (Jan 1 - Mar 31)
REGENXBIO INC.
Filed by LMH STRATEGIC SOLUTIONS.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 17, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- LMH STRATEGIC SOLUTIONS
- Client
- REGENXBIO INC.
- Filing UUID
- 7e5f0dd7-77b1-4a13-a51c-0cb7d4992c9b
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.